This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (22) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Reneman, L. Articles by den Heeten, G. J. Search for Related Content PubMed PubMed Citation Articles by Reneman, L. Articles by den Heeten, G. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 3,4-METHYLENEDIOXYMETHAMPHETAMINE Medline Plus Health Information Club Drugs Nuclear Scans Social Bookmarking                         What's this?

Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects

Maartje M. L. de Win

Graduate School of Neurosciences, Department of Radiology, Academic Medical Centre, AZ 1105 University of Amsterdam, Amsterdam, The Netherlands

Wim van den Brink

Amsterdam Institute for Addiction Research and Department of Psychiatry, Academic Medical Centre, AZ 1105 University of Amsterdam, Amsterdam, The Netherlands

Jan Booij

Department of Nuclear Medicine, Academic Medical Centre, AZ 1105 University of Amsterdam, Amsterdam, The Netherlands

Gerard J. den Heeten

Graduate School of Neurosciences, Department of Radiology, Academic Medical Centre, AZ 1105 University of Amsterdam, Amsterdam, The Netherlands

Users of ecstasy (3,4-methylenedioxymethamphetamine; MDMA) may be at risk of developing MDMA-induced injury to the serotonin (5-HT) system. Previously, there were no methods available for directly evaluating the neurotoxic effects of MDMA in the living human brain. However, development of in vivoneuroimaging tools have begun to provide insights into the effects of ecstasy on the human brain. Single photon emission computed tomography (SPECT), positron emission computed tomography (PET) and proton magnetic resonance spectroscopy (1H-MRS) studies which have evaluated ecstasy's neurotoxic potential will be reviewed and discussed in terms of technical aspects, conceptual issues and future prospects. Although PET and SPECT may be limited by several factors such as the low cortical uptake and the use of a non-optimal reference region (cerebellum) the few studies conducted so far provide suggestive evidence that people who heavily use ecstasy are at risk of developing subcortical, and probably also cortical reductions in serotonin transporter (SERT) densities, a marker of 5-HT neurotoxicity. There seem to be dose-dependent and transient reductions in SERT for which females may be more vulnerable than males. 1H-MRS appears to be a less sensitive technique for studying ecstasy's neurotoxic potential. Whether individuals with a relatively low ecstasy exposure also demonstrate loss of SERT needs to be determined. Because most studies have had a retrospective design, in which evidence is indirect and differs in the degree to which any causal links can be implied, longitudinal studies in human ecstasy users are needed to draw de.nite conclusions.

Key Words: ecstasy • MDMA • neuroimaging • serotonin • SPECT • 1H-MRSpectroscopy

Journal of Psychopharmacology, Vol. 20, No. 2, 164-175 (2006)
DOI: 10.1177/0269881106061515


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Kish, P. Fitzmaurice, L. Chang, Y. Furukawa, and J. Tong Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study J Psychopharmacol, February 1, 2010; 24(2): 281 - 284. [Abstract] [PDF]

				S. Selvaraj, R. Hoshi, Z. Bhagwagar, N. V. Murthy, R. Hinz, P. Cowen, H. V. Curran, and P. Grasby Brain serotonin transporter binding in former users of MDMA ('ecstasy') The British Journal of Psychiatry, April 1, 2009; 194(4): 355 - 359. [Abstract] [Full Text] [PDF]

				J. Fisk and C. Montgomery Evidence for selective executive function deficits in ecstasy/polydrug users J Psychopharmacol, January 1, 2009; 23(1): 40 - 50. [Abstract] [PDF]

				M. M. L. de Win, G. Jager, J. Booij, L. Reneman, T. Schilt, C. Lavini, S. D. Olabarriaga, G. J. den Heeten, and W. van den Brink Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users Brain, November 1, 2008; 131(11): 2936 - 2945. [Abstract] [Full Text] [PDF]

				M. M. L. de Win, G. Jager, J. Booij, L. Reneman, T. Schilt, C. Lavini, S. D. Olabarriaga, N. F. Ramsey, G. J. d. Heeten, and W. van den Brink Neurotoxic effects of ecstasy on the thalamus The British Journal of Psychiatry, October 1, 2008; 193(4): 289 - 296. [Abstract] [Full Text] [PDF]

				A. C. Parrott Ecstasy versus alcohol: Tolstoy and the variations of unhappiness J Psychopharmacol, January 1, 2007; 21(1): 3 - 6. [PDF]

				E. D. Willers and J. H. Newman New Risks for Pulmonary Hypertension: Need for a Large Epidemiologic Study Chest, December 1, 2006; 130(6): 1633 - 1635. [Full Text] [PDF]